A dual amylin and calcitonin receptor agonist inhibits pain behavior and reduces cartilage pathology in an osteoarthritis rat model
-
Add time:07/21/2019 Source:sciencedirect.com
SummaryObjectivesPain and disability are the main clinical manifestations of osteoarthritis, for which only symptomatic therapies are available. Hence, there is a need for therapies that can simultaneously alter disease progression and provide pain relief. KBP is a dual amylin- and calcitonin-receptor agonist with antiresorptive and chondroprotective properties. In this study we investigated the effect of KBP in a rat model of osteoarthritis.
We also recommend Trading Suppliers and Manufacturers of CALCITONIN, RAT (cas 11118-25-5). Pls Click Website Link as below: cas 11118-25-5 suppliers
Prev:Preparation and characterization of solid lipid nanoparticles loaded with salmon calcitonin phospholipid complex
Next:Hexapeptide-conjugated calcitonin for targeted therapy of osteoporosis) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Potentiation of capsaicin-induced neurogenic inflammation by 5-HT7 receptors in the rat hind paw: Involvement of calcitonin gen-related peptide07/26/2019
- Platypus and opossum calcitonins exhibit strong activities, even though they belong to mammals07/25/2019
- Calcitonin-gene related peptide is a potent inducer of oedema in rat orofacial tissue07/24/2019
- Low-Intensity Pulsed Ultrasound-Induced Spinal Fusion is Coupled with Enhanced Calcitonin Gene-Related Peptide Expression in Rat Model07/23/2019
- Calcitonin as an anticalcification treatment for implantable biological tissues07/22/2019
- Hexapeptide-conjugated calcitonin for targeted therapy of osteoporosis07/20/2019
- Preparation and characterization of solid lipid nanoparticles loaded with salmon calcitonin phospholipid complex07/19/2019
- Development and characterization of supramolecular calcitonin assembly and assessment of its interactions with the bone remodelling process07/18/2019
